

## News Release

# Stefan Verseck Joins Lonza as Technology Scout and Biotechnology Expert

**South Plainfield, NJ (USA), 17 April 2018** – Stefan Verseck, PhD, has joined Lonza's Consumer Product Ingredients (CPI) organization as Technology Scout and Biotechnology Expert for the Personal Care, Hygiene and Preservation businesses.

Based in Cologne (DE), Dr. Verseck will lead all efforts to identify innovative technologies to accelerate new product development. In addition, he will support and strengthen Lonza's existing CPI product portfolio by identifying novel applications and creating synergies with newly identified technologies.

Prior to joining Lonza this month, Dr. Verseck served six years as the head of Lipid Biotechnology for BASF Personal Care and Nutrition GmbH. He has held various R&D and Biotechnology roles at Cognis GmbH and Degussa AG/Evonik Degussa GmbH.

Dr. Verseck earned his PhD in Expression of Microbial Enzymes from the University of Wuppertal (DE), a Master's degree in Biology from Westfälische Wilhelms University (DE), and a Bachelor's degree in Biology from Rheinische Friedrich-Wilhelms-University (DE). Throughout his career he has contributed to a number of publications in renowned international journals.

### About Lonza Consumer Product Ingredients – Personal Care

Part of Lonza's Consumer Product Ingredients business unit, the Personal Care business is a world's leading supplier of active antidandruff agents, with its Zinc Omadine® product considered the gold standard in the antidandruff shampoo market. Lonza Personal Care also supplies a wide array of other hair- and skin-care products, including biotechnology-derived active ingredients, preservatives for use in certified natural and organic products, specialty esters, functional ingredients and more. More information about these products can be found at [www.lonza.com/personalcare](http://www.lonza.com/personalcare).

### About Lonza

Lonza is one of the world's leading and most-trusted suppliers to the pharmaceutical, biotech and specialty

ingredients markets. As an integrated solutions provider, Lonza is boosting its value creation along and beyond the healthcare continuum with a strong focus on patient healthcare, consumer preventive healthcare and consumer's healthy environment.

Lonza harnesses science and technology to create products that support safer and healthier living and that enhance the overall quality of life. With the recent Capsugel acquisition, Lonza now offers products and services from the custom development and manufacturing of active pharmaceutical ingredients to innovative dosage forms for the pharma and consumer health and nutrition industries.

Benefiting from its regulatory expertise, Lonza is able to transfer its know-how from pharma to hygiene and fast-moving consumer goods all the way to coatings and composites and the preservation and protection of agricultural goods and other natural resources.

Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 100 sites and offices and approximately 14,500 full-time employees worldwide. The company generated sales of CHF 5.1 billion in 2017 with a CORE EBITDA of CHF 1.3 billion. Further information can be found at [www.lonza.com](http://www.lonza.com).

### Lonza Contact Details

Charlie Gins, Global Marketing Communications Specialist  
Lonza Inc.

Tel +1 201 316-9497

[charlie.gins@lonza.com](mailto:charlie.gins@lonza.com)

### Constance Ward, Head External Communications

Lonza Group Ltd

Tel +41 61 316 8840

[constance.ward@lonza.com](mailto:constance.ward@lonza.com)

### Additional Information and Disclaimer

Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited ("SGX-ST"). Lonza Group Ltd is not subject to the SGX-ST's continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.



## Personal Care

Lonza Inc.  
90 Boroline Road  
Allendale, NJ 07401USA  
+1 201 316 9200  
+1 201 785 9973  
[contact.allendale@lonza.com](mailto:contact.allendale@lonza.com)

# Lonza

Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this presentation due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this release.